5.44

0.00% 0.00

Relmada Therapeutics Inc (RLMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Relmada Therapeutics Inc stock is traded at $5.44, with a volume of 353.70K. It is up +0.00% in the last 24 hours and down -14.06% over the past month. Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Previous Close:

$5.44

Open:

$5.44

24h Volume:

353.70K

Relative Volume:

0.22

Market Cap:

$566.93M

Revenue:

Net Income/Loss:

$-58.88M

P/E Ratio:

-4.8903

EPS:

-1.1124

Net Cash Flow:

$-42.79M

1W Performance:

+1.68%

1M Performance:

-14.06%

6M Performance:

+40.21%

1Y Performance:

+808.18%

1-Day Range:

$5.35

$5.575

1-Week Range:

$5.00

$5.575

52-Week Range:

$0.55

$8.00

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name

Relmada Therapeutics Inc

Sector

Healthcare (1083)

Industry

Biotechnology (604)

Phone

646 876 3459

Address

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Employee

Twitter

@relmada

Next Earnings Date

2026-08-06

Latest SEC Filings

RLMD's Discussions on Twitter

Compare RLMD vs MOBBW, GOODO, PSNYW, SHMD, DWLD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLMD	3.03	0	0	0	0	0.00
MOBBW Mobilicom Limited Warrants	1.76	2.64B	0	0	0	0.00
GOODO Gladstone Commercial Corporation	20.66	372.90M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	2.45	375.29M	2.07B	-1.42B	-1.37B	-0.6765
SHMD Schmid Group N V	4.42	281.75M	52.15M	-21.46M	0	-0.4675
DWLD Davis Select Worldwide ETF	47.97	0	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-24-26	Initiated	Piper Sandler	Overweight
Jan-23-26	Resumed	Leerink Partners	Outperform
Dec-22-25	Initiated	Jefferies	Buy
Nov-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral
Sep-17-24	Upgrade	Jefferies	Hold → Buy
Jun-05-24	Downgrade	Goldman	Neutral → Sell
Oct-14-22	Downgrade	Goldman	Buy → Neutral
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Truist	Buy → Hold
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform
Nov-18-21	Initiated	Mizuho	Buy
May-20-21	Resumed	Goldman	Buy
Oct-28-20	Downgrade	Goldman	Buy → Neutral
Jul-14-20	Initiated	Oppenheimer	Outperform
May-04-20	Initiated	SunTrust	Buy
Apr-21-20	Initiated	Goldman	Buy
Jan-27-20	Initiated	Jefferies	Buy
Jan-10-20	Initiated	SVB Leerink	Outperform
Dec-16-19	Initiated	Guggenheim	Buy

View All

Relmada Therapeutics Inc Stock (RLMD) Latest News

Jul 28, 2026

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer - Investing News Network

Jul 28, 2026

Relmada Therapeutics (RLMD) Names Bipin Dalmia as Chief Business Officer Amid Strategic Growth Focus - GuruFocus

Jul 28, 2026

Relmada Therapeutics, Inc. Announces Appointment of Bipin Dalmia as Chief Business Officer - marketscreener.com

Jul 28, 2026

Relmada Therapeutics Appoints New Chief Business Officer - TipRanks

Jul 28, 2026

Relmada names Bipin Dalmia as chief business officer By Investing.com - Investing.com Canada

Jul 28, 2026

Relmada names Bipin Dalmia as Chief Business Officer to advance NDV-01 and commercial strategy - TradingView

Jul 28, 2026

Jul 27, 2026